Exhibit 99.1 CLEARMIND MEDICINE INC. Condensed Interim Consolidated Financial Statements For The Three and Six Months Ended April 30, 2025 (Expressed in United States Dollars) (Unaudited) CLEARMIND MEDICINE INC. Condensed Interim Consolidated Statements of Financial Position (Expressed in United States Dollars) (Unaudited) | | April 30, | | October 31, | | --- | --- | --- | --- | | | 2025 | | 2024 | | Assets | | | | | Current assets | | | | | Cash and cash equivalents | $ 4,472,520 | | $ 6,573,813 | | Other ...

Core Insights - Clearmind Medicine Inc. has engaged a leading government and political affairs consulting firm to advance its mission of developing psychedelic-based therapeutics [1][2] - The company aims to navigate complex regulatory landscapes and promote acceptance of psychedelic therapies among U.S. policymakers [2][3] - Clearmind's lead candidate, CMND-100, is currently in Phase I/IIa clinical trials for alcohol use disorder (AUD) at prestigious institutions [3] Company Overview - Clearmind is a clinical-stage biotech company focused on discovering and developing psychedelic-derived therapeutics to address under-treated health issues, including AUD [4] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as needed [5] Industry Context - The pharmaceutical industry is increasingly recognizing the potential of psychedelics to treat mental health disorders such as PTSD [2] - The partnership with the consulting firm aims to educate policymakers on the therapeutic potential of psychedelics and support the development of balanced regulations [3]

Core Insights - Clearmind Medicine Inc. has initiated a Phase I/IIa clinical trial for CMND-100, a novel oral drug candidate aimed at treating Alcohol Use Disorder (AUD), with the first patient enrolled at Yale School of Medicine [1][2] - The trial will assess the safety, tolerability, and pharmacokinetic profile of CMND-100, along with preliminary efficacy in reducing alcohol cravings and consumption [2] - The U.S. substance use disorder treatment market was valued at $35.1 billion in 2021 and is projected to grow to $60.2 billion by 2029, highlighting significant market potential for effective AUD treatments [3] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address major health issues, including AUD [4] - The company holds a robust intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as needed [5] Clinical Trial Details - Eligible participants for the trial include individuals aged 18 to 60, either heavy binge drinkers or those diagnosed with AUD, who express a desire to reduce or stop drinking [3] - The trial is being conducted at multiple sites, including Yale School of Medicine and Johns Hopkins University School of Medicine, with additional sites under evaluation [3]

Core Insights - SciSparc Ltd. has announced a collaboration with Clearmind Medicine Inc. that has resulted in a European patent application for a combination treatment targeting cocaine addiction [1][4] - The patent application is based on preclinical trial results showing that Clearmind's MEAI significantly reduces cocaine-induced craving in animal models [2] - Further research indicates that MEAI specifically targets drug-related compulsions without impairing responses to natural rewards, suggesting a focused mechanism of action [3] Company Overview - SciSparc Ltd. is a clinical-stage pharmaceutical company specializing in cannabinoid pharmaceuticals, with ongoing drug development programs for conditions such as Tourette Syndrome, Alzheimer's disease, and autism [5] - Clearmind Medicine Inc. is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics for health issues like alcohol use disorder, holding a portfolio of 19 patent families and 31 granted patents [6]

Core Insights - Clearmind Medicine Inc. has announced the publication of a European patent application, strengthening its global intellectual property position and focusing on addiction treatment [1][2] Intellectual Property - The patent EP 4531826 covers Clearmind's proprietary psychedelic-based combination therapy, which includes MEAI and certain N-Acylethanolamines for treating cocaine addiction [2] - The company's intellectual portfolio consists of nineteen patent families, including 31 granted patents, with plans to seek additional patents as warranted [7] Research and Development - Preclinical trials led by Professor Gal Yadid at Bar-Ilan University demonstrated that MEAI significantly reduced cocaine-induced cravings in animals [3] - Further studies showed that MEAI reduced cocaine-seeking behavior without impairing responses to natural rewards, indicating a targeted effect on drug-related compulsions [4] Strategic Collaboration - The patent application is part of an ongoing collaboration with SciSparc Ltd. to explore the combined potential of MEAI and PEA-based technologies for treating central nervous system disorders [5] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics for under-treated health problems, including substance use disorders [6]

Core Insights - SciSparc Ltd. has announced a collaboration with Clearmind Medicine Inc. leading to the filing of a new international patent application for a treatment targeting anorexia, bulimia, and other eating disorders [1][2] Company Overview - SciSparc Ltd. is a specialty clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders, with a portfolio that includes cannabinoid pharmaceuticals [4] - The company is engaged in drug development programs targeting conditions such as Tourette Syndrome, Alzheimer's disease, and autism spectrum disorder [4] Collaboration Details - The patent application involves the use of 3-Methylmethcathinone (3-MMC) in combination with SciSparc's Palmitoylethanolamide (PEA), aiming to address neurobiological and psychological factors associated with eating disorders [2] Industry Context - Eating disorders are serious mental health conditions affecting up to 70 million people globally, with a prevalence increase from 3.4% to 7.8% between 2000 and 2018 [3] - These disorders are among the top ten leading causes of disability among young women and have one of the highest mortality rates compared to other mental disorders [3] Clearmind Medicine Overview - Clearmind Medicine Inc. is a clinical-stage psychedelic pharmaceutical biotech company focused on developing psychedelic-derived therapeutics for health issues like alcohol use disorder [5] - The company holds a portfolio of nineteen patent families, including 31 granted patents, and aims to expand its intellectual property [6]

Core Viewpoint - Clearmind Medicine Inc. has filed a new international patent application for a proprietary treatment targeting anorexia, bulimia, and other eating disorders, highlighting its commitment to developing innovative therapies for under-treated mental health conditions [1][4]. Company Overview - Clearmind Medicine Inc. is a clinical-stage biotech company focused on the discovery and development of novel psychedelic-derived therapeutics aimed at addressing significant health issues, including eating disorders and alcohol use disorder [5]. - The company currently holds an intellectual property portfolio consisting of nineteen patent families, including 31 granted patents, and plans to seek additional patents as warranted [6]. Treatment Development - The new patent application covers the use of 3-Methylmethcathinone (3-MMC) in combination with Palmitoylethanolamide (PEA), targeting the neurobiological and psychological factors associated with eating disorders [2]. - The company aims to provide new treatment options for individuals struggling with eating disorders through the therapeutic potential of 3-MMC and PEA [4]. Industry Context - Eating disorders are serious mental health conditions that significantly impact health, emotions, and daily functioning, with up to 70 million people affected globally [3]. - The prevalence of eating disorders increased from 3.4% to 7.8% between 2000 and 2018, indicating a growing public health concern [3].

Core Viewpoint - Clearmind Medicine Inc. has initiated its U.S. clinical trial for its psychedelic-derived treatment CMND-100 aimed at addressing Alcohol Use Disorder (AUD), marking a significant step in the development of innovative therapies for this under-treated health issue [1][3]. Group 1: Clinical Trial Details - The clinical trial site at Yale School of Medicine's Department of Psychiatry has been activated, with patient enrollment set to begin [1]. - The trial will be led by Dr. Anahita Bassir Nia, M.D., and will also take place at Johns Hopkins University School of Medicine and the IMCA Center in Israel [2]. Group 2: Company Overview and Objectives - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address significant health problems, including AUD [4]. - The company aims to research and commercialize psychedelic-based compounds as regulated medicines, foods, or supplements [4]. Group 3: Intellectual Property - Clearmind's intellectual property portfolio includes nineteen patent families and 31 granted patents, with plans to seek additional patents as necessary [5].

Core Insights - Clearmind Medicine Inc. is hosting a live webinar titled "Gazing Through the Crystal Ball" on May 21, 2025, focusing on the evolving landscape of psychedelic science and business amid changing FDA policies and political climates [1] - The company is a clinical-stage biotech firm dedicated to developing psychedelic-derived therapeutics to address significant under-treated health issues, particularly Alcohol Use Disorder (AUD) [7] Event Details - The webinar will feature a panel of experts, including Rick Doblin, PhD, a pioneer in psychedelic-assisted therapy; Robin Carhart-Harris, PhD, known for his work in psychedelic neuroscience; and Dr. Adi Zuloff-Shani, CEO of Clearmind, who is leading the development of CMND-100 for AUD [2][3][4] - The discussion will be moderated by Shannon Smadella, a recognized advocate in the psychedelic space [6] Company Overview - Clearmind's primary objective is to research and develop psychedelic-based compounds for commercialization as regulated medicines, foods, or supplements [7] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as necessary [8]

Vancouver, Canada, April 21, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, is pleased to announce its upcoming live webinar titled "Gazing Through the Crystal Ball." The event is scheduled for May 21, 2025, at 12:00 PM ET (9:00 AM PT) and will feature a distinguished panel of experts discuss ...